Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

作者: Karthika Natarajan , Yingqiu Xie , Mehmet Burcu , Douglas E. Linn , Yun Qiu

DOI: 10.1371/JOURNAL.PONE.0074653

关键词:

摘要: The type III receptor tyrosine kinase fms-like 3 (FLT3) is expressed on both normal hematopoietic stem cells and acute myeloid leukemia (AML) regulates their proliferation. Internal tandem duplication (ITD) mutation of FLT3 present in a third AML cases, results constitutive activation aberrant signaling FLT3, associated with adverse treatment outcomes. While wild-type (WT) predominantly 150 kDa complex glycosylated cell surface protein, FLT3-ITD partially retained the endoplasmic reticulum as 130 underglycosylated species chaperones calnexin heat shock protein (HSP) 90, mediates STAT5 signaling, which upregulates oncogenic serine/threonine Pim-1. contains Pim-1 substrate consensus serine phosphorylation site, we hypothesized that it might be substrate. was indeed found to directly interact serine-phosphorylate FLT3. inhibition decreased expression half-life partial abrogation by proteasome inhibition, association binding HSP90, increased half-life, glycosylation. These findings were consistent stabilizing HSP90 inhibiting its glycosylation form species. knockdown effects similar. also at 591 STAT5, itself, FLT3-ITD-STAT5 pathway. Finally, synergized inducing apoptosis cells. This is, our knowledge, first demonstration role positive feedback loop promoting malignant

参考文章(48)
Y Minami, H Kiyoi, Y Yamamoto, K Yamamoto, R Ueda, H Saito, T Naoe, Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. ,vol. 16, pp. 1535- 1540 ,(2002) , 10.1038/SJ.LEU.2402558
Kyu-Tae Kim, Kristin Baird, Joon-Young Ahn, Paul Meltzer, Michael Lilly, Mark Levis, Donald Small, Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. ,vol. 105, pp. 1759- 1767 ,(2005) , 10.1182/BLOOD-2004-05-2006
Yingqiu Xie, Kexin Xu, Douglas E. Linn, Xi Yang, Zhiyong Guo, Hermela Shimelis, Takeo Nakanishi, Douglas D. Ross, Hegang Chen, Ladan Fazli, Martin E. Gleave, Yun Qiu, The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. Journal of Biological Chemistry. ,vol. 283, pp. 3349- 3356 ,(2008) , 10.1074/JBC.M707773200
Toshihiro Mochizuki, Chifumi Kitanaka, Kohji Noguchi, Tomonari Muramatsu, Akio Asai, Yoshiyuki Kuchino, Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. Journal of Biological Chemistry. ,vol. 274, pp. 18659- 18666 ,(1999) , 10.1074/JBC.274.26.18659
C K Palaty, I Clark-Lewis, D Leung, S L Pelech, Phosphorylation site substrate specificity determinants for the PIM-1 protooncogene-encoded protein kinase Biochemistry and Cell Biology. ,vol. 75, pp. 153- 162 ,(1997) , 10.1139/O97-026
Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl D. Cramer, Michael F. Gardner, Daniel Brigham, Barbara Belli, Mazen W. Karaman, Keith W. Pratz, Gabriel Pallares, Qi Chao, Kelly G. Sprankle, Hitesh K. Patel, Mark Levis, Robert C. Armstrong, Joyce James, Shripad S. Bhagwat, AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood. ,vol. 114, pp. 2984- 2992 ,(2009) , 10.1182/BLOOD-2009-05-222034
Xuerong Wang, Ping Yue, Young Ae Kim, Haian Fu, Fadlo R. Khuri, Shi-Yong Sun, Enhancing Mammalian Target of Rapamycin (mTOR)–Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation Cancer Research. ,vol. 68, pp. 7409- 7418 ,(2008) , 10.1158/0008-5472.CAN-08-1522
R. R. Ramos, A. J. Swanson, J. Bass, Calreticulin and Hsp90 stabilize the human insulin receptor and promote its mobility in the endoplasmic reticulum Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 10470- 10475 ,(2007) , 10.1073/PNAS.0701114104
Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, Robert K. Stuart, Michele Baccarani, Larry D. Cripe, Martin S. Tallman, Giovanna Meloni, Lucy A. Godley, Amelia A. Langston, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, Dan Douer, W. Wiktor-Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M. Bensen-Kennedy, Donald Small, B. Douglas Smith, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Blood. ,vol. 117, pp. 3294- 3301 ,(2011) , 10.1182/BLOOD-2010-08-301796